Amerinet to distribute IsoAid brachytherapy products

IsoAid has been awarded a three-year contract to provide members of the healthcare group purchasing organization Amerinet with its line of brachytherapy products, used primarily in the treatment of prostate cancer.

The agreement, which will begin on Oct. 1, offers Amerinet’s membership market pricing and access to IsoAid’s Advantage I-125 and Advantage Pd-103 seeds and related brachytherapy products, according to the Port Richey, Fla.-based IsoAid.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.